Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients with Heart Failure and Hyperkalemia

In this episode, Dr. Valentin Foster highlights a groundbreaking study published in the October 2024 issue of JACC, which explores how patiromer facilitates the effective use of angiotensin inhibitors and mineralocorticoid antagonists in heart failure patients at risk of hyperkalemia. Authored by Dr. Bertram Pete and colleagues, the research demonstrates that patiromer not only helps achieve optimal medication doses but also improves potassium management, ultimately enhancing patient outcomes in this high-risk population.